Cancer Research · us
Training the Immune System Before Cancer Appears: KRAS Vaccine Takes First Step Toward Pancreatic Cancer Interception
A 20-person Phase 1 trial showed that mKRAS-VAX can induce mutation-specific T-cell responses lasting up to two years in people at high risk of pancreatic cancer; this is a feasibility signal, not yet proof that the vaccine can prevent cancer.
Pancreatic cancer is often already difficult to cure by the time symptoms appear. Rather than waiting to treat a tumor after it forms, researchers are therefore trying to move the line of defense forward: teaching the immune systems of people with inherited risk and pancreatic imaging abnormalities to recognize KRAS mutations commonly found in the early stages of malignant transformation. A first-in-human trial showed that this “cancer interception” approach can at least safely initiate durable immune responses, but there is still a long way to go before it can be shown to prevent cancer.
This Phase 1 study enrolled 20 participants with an inherited predisposition to pancreatic ductal adenocarcinoma and pancreatic abnormalities detected through imaging. The experimental mKRAS-VAX vaccine contains synthetic peptides representing six mutant KRAS antigens—G12D, G12V, G12R, G12A, G12C, and G13D—and is administered with the poly-ICLC adjuvant to broaden the immune system’s ability to recognize potentially precancerous cells.
After vaccination, 18 people, or 90% of participants, developed significant mutant KRAS-specific T-cell responses. Of these, 10 responded to all six antigens, with G12A, G12V, and G12R eliciting the highest median response intensity. T-cell receptor sequencing further identified cell clones that emerged after vaccination, some of which remained detectable for up to two years, indicating that this was not a fleeting immune fluctuation.
The safety findings also met the primary objective of a Phase 1 trial: all adverse events were Grade 1 or Grade 2, with no events of Grade 3 or higher. The most common were injection-site reactions, occurring in 85% of participants; 70% experienced fatigue, while chills and flu-like symptoms each occurred in 40%. These data support further research but cannot be used to directly infer the long-term risks and benefits of vaccination for the broader high-risk population.
During a median follow-up of 16.5 months, no participant developed pancreatic ductal adenocarcinoma. An exploratory post hoc analysis also found that pancreatic cysts shrank or disappeared in 6 of 16 evaluable participants. The study report compared this result with an independently monitored, unvaccinated group, but the two groups were not randomly assigned and the sample was small. It is therefore impossible to confirm that the cyst changes were caused by the vaccine or to interpret the absence of cancer to date as successful prevention.
Independent experts believe the study’s most robust findings concern safety and immunogenicity, not clinical efficacy. The next step will require larger trials with appropriate controls and longer follow-up to determine whether the immune responses can actually reduce cancer incidence. The scope of applicability is another limitation: the study targeted people with inherited familial risk, while most patients with sporadic pancreatic cancer may not have a sufficiently early or clearly defined opportunity for vaccination.